Nasdaq

Allergan Receives FDA Approval for DURYSTA™ (bimatoprost implant) the First and Only Intracameral Biodegradable Sustained-Release Implant to lower Intraocular Pressure in ...

- DURYSTA™ lowered intraocular pressure in patients with open-angle glaucoma or ocular hypertension by approximately 30 percent from baseline in two Phase 3 studies - - Allergan continues five ongoing ...
Medindia

Dr. James C. Loden, The First Surgeon to Implant Durysta in a Glaucoma Patient in Tennesee

NASHVILLE, Tenn., Aug. 3, 2020 /PRNewswire-PRWeb/ -- Loden Vision Centers, a leading comprehensive ophthalmology company with 5 locations across the greater Nashville and surrounding areas, has ...
The Gazette

Colorado Springs eye practice delivers ‘a game changer’ — 1st in Colorado with new treatment

Dr. Roman Krivochenitser, right, talks with patient Doris Winn, 81, after her procedure for a treatment called Durysta, in which a tiny pellet is injected into the eye that releases medication over a ...
Healio

Perspective: I. Paul Singh, MD, on the FDA approval of Durysta

Please provide your email address to receive an email when new articles are posted on . The recent paradigm shift in the treatment of glaucoma moving toward earlier intervention, better managing ...
Business Insider

Allergan Receives FDA Approval for DURYSTA™ (bimatoprost implant) the First and Only Intracameral Biodegradable Sustained-Release Implant to lower Intraocular Pressure in ...

DUBLIN, March 5, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, today announced that the U.S. Food and Drug ...